TTRX · Turn Therapeutics Inc. · Executive Compensation
$9.48
+0.54 (+6.04%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$282.39M
Shares
29.79M
Volume · Nov 6
98.14K
Avg daily vol (3M)
110.55K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Zuraiz Chaudhary | Interim Chief Financial Officer | $1,426,754 |
| Bradley Burnam | Chief Executive Officer | $652,036 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Bradley Burnam | Chief Executive Officer | $429,320 |
| Zuraiz Chaudhary | Interim Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Martin Dewhurst | independent Class III director | Appointed | 2026-01-07 |
| Dr. Kent Kester | director | Appointed | 2025-10-02 |
| Arthur Golden | director | Appointed | 2025-10-02 |
Leadership
- Bradley Burnam CEO, Board Member
- Zuraiz Chaudhary CFO
- Andrew Gengos Board Member
- Arthur Golden Board Member
- Dr. Kent Kester Board Member
- Dr. Neil Ghodadra Board Member
- Martin Dewhurst Board Member
Key facts
CIK
2023016
CUSIP
90021W105
13F (30d)
16 filings
16 filers
Visit website
Investor relations